Last reviewed · How we verify
Indoximod HCL F1 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Indoximod HCL F1 (Indoximod HCL F1) — NewLink Genetics Corporation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Indoximod HCL F1 TARGET | Indoximod HCL F1 | NewLink Genetics Corporation | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Indoximod HCL F1 CI watch — RSS
- Indoximod HCL F1 CI watch — Atom
- Indoximod HCL F1 CI watch — JSON
- Indoximod HCL F1 alone — RSS
Cite this brief
Drug Landscape (2026). Indoximod HCL F1 — Competitive Intelligence Brief. https://druglandscape.com/ci/indoximod-hcl-f1. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab